04:08 AM EDT, 06/02/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer.

The company said its combination therapy reduced the risk of disease progression or death by 56% compared with standard treatment, with patients experiencing a median progression-free survival of 16 months versus 9.2 months for standard-of-care treatment.

The drugmaker said its therapy also delayed quality-of-life deterioration and pain.

AstraZeneca ( AZN ) said data for key secondary endpoints of time to second disease progression and overall survival were immature at the time of the interim analysis.